118 related articles for article (PubMed ID: 19066322)
1. Severe pseudomembranous colitis after moxifloxacin use: a case series.
Gallagher JC; Du JK; Rose C
Ann Pharmacother; 2009 Jan; 43(1):123-8. PubMed ID: 19066322
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea.
Vasa CV; Glatt AE
Am J Gastroenterol; 2003 Feb; 98(2):354-8. PubMed ID: 12591054
[TBL] [Abstract][Full Text] [Related]
3. Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2005 Dec; 54(47):1201-5. PubMed ID: 16319813
[TBL] [Abstract][Full Text] [Related]
4. Clostridium difficile-associated diarrhoea in patients with human immunodeficiency virus infection: a case-control study.
Tumbarello M; Tacconelli E; Leone F; Cauda R; Ortona L
Eur J Gastroenterol Hepatol; 1995 Mar; 7(3):259-63. PubMed ID: 7743309
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain.
Biller P; Shank B; Lind L; Brennan M; Tkatch L; Killgore G; Thompson A; McDonald LC
Infect Control Hosp Epidemiol; 2007 Feb; 28(2):198-201. PubMed ID: 17265402
[TBL] [Abstract][Full Text] [Related]
6. Emergence of Clostridium difficile-associated disease in North America and Europe.
Kuijper EJ; Coignard B; Tüll P; ; ;
Clin Microbiol Infect; 2006 Oct; 12 Suppl 6():2-18. PubMed ID: 16965399
[TBL] [Abstract][Full Text] [Related]
7. A study of Clostridium difficile-associated disease at King Chulalongkorn Memorial Hospital, Thailand.
Pupaibool J; Khantipong M; Suankratay C
J Med Assoc Thai; 2008 Jan; 91(1):37-43. PubMed ID: 18386542
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin-associated neutropenia in a cirrhotic elderly woman with lower extremity cellulitis.
Chang CM; Lee NY; Lee HC; Lee IW; Wu CJ; Lin YS; Ko WC
Ann Pharmacother; 2008 Apr; 42(4):580-3. PubMed ID: 18349304
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score.
Kim YG; Graham DY; Jang BI
J Clin Gastroenterol; 2012; 46(5):397-400. PubMed ID: 22298089
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea.
Juang P; Skledar SJ; Zgheib NK; Paterson DL; Vergis EN; Shannon WD; Ansani NT; Branch RA
Am J Infect Control; 2007 Mar; 35(2):131-7. PubMed ID: 17327194
[TBL] [Abstract][Full Text] [Related]
11. Moxifloxacin prophylaxis in neutropenic patients.
von Baum H; Sigge A; Bommer M; Kern WV; Marre R; Döhner H; Kern P; Reuter S
J Antimicrob Chemother; 2006 Oct; 58(4):891-4. PubMed ID: 16880172
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin-induced Clostridium difficile-associated diarrhea.
Carroll DN
Pharmacotherapy; 2003 Nov; 23(11):1517-9. PubMed ID: 14620398
[TBL] [Abstract][Full Text] [Related]
13. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.
Zar FA; Bakkanagari SR; Moorthi KM; Davis MB
Clin Infect Dis; 2007 Aug; 45(3):302-7. PubMed ID: 17599306
[TBL] [Abstract][Full Text] [Related]
14. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.
Pépin J; Saheb N; Coulombe MA; Alary ME; Corriveau MP; Authier S; Leblanc M; Rivard G; Bettez M; Primeau V; Nguyen M; Jacob CE; Lanthier L
Clin Infect Dis; 2005 Nov; 41(9):1254-60. PubMed ID: 16206099
[TBL] [Abstract][Full Text] [Related]
15. The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea.
Novell MJ; Morreale CA
Ann Pharmacother; 2010 May; 44(5):826-31. PubMed ID: 20354161
[TBL] [Abstract][Full Text] [Related]
16. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents.
Nomura K; Fujimoto Y; Yamashita M; Morimoto Y; Ohshiro M; Sato K; Oyake T; Kowata S; Konishi H; Yoshikawa T; Ishida Y; Taniwaki M;
Scand J Gastroenterol; 2009; 44(1):74-8. PubMed ID: 18781540
[TBL] [Abstract][Full Text] [Related]
17. [Clostridium difficile diarrhea: frequency of detection in a medical center in Buenos Aires, Argentina].
Fernandez Canigia L; Nazar J; Arce M; Dadamio J; Smayevsky J; Bianchini H
Rev Argent Microbiol; 2001; 33(2):101-7. PubMed ID: 11494752
[TBL] [Abstract][Full Text] [Related]
18. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients.
Aseeri M; Schroeder T; Kramer J; Zackula R
Am J Gastroenterol; 2008 Sep; 103(9):2308-13. PubMed ID: 18702653
[TBL] [Abstract][Full Text] [Related]
19. Who are susceptible to pseudomembranous colitis among patients with presumed antibiotic-associated diarrhea?
Lee KS; Shin WG; Jang MK; Kim HS; Kim HS; Park CJ; Lee JY; Kim KH; Park JY; Lee JH; Kim HY; Cho SJ; Yoo JY
Dis Colon Rectum; 2006 Oct; 49(10):1552-8. PubMed ID: 17028914
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical features of Clostridium difficile-associated diarrhea in a tertiary hospital in northern Taiwan.
Hsu MS; Wang JT; Huang WK; Liu YC; Chang SC
J Microbiol Immunol Infect; 2006 Jun; 39(3):242-8. PubMed ID: 16783456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
